photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer

FOLFIRINOX as Neoadjuvant Therapy for Pancreatic Cancer

The idea behind treating surgically unresectable and borderline resectable pancreatic cancer (ductal adenocarcinoma of the pancreas) with chemotherapy or chemoradiation is that some minority of cases will thereupon improve to the point of now being deemed amenable to surgery, with its typically more favorable outcome.  This is generally the point then of so-called neoadjuvant therapy. […]

Biomarker miR-10b for Pancreatic Cancer: earlier diagnosis and/or therapeutic target?

As alluded to in another recent blog entry, the study of microRNA has been a source of great interest as to the possible development of biomarkers that may screen or aid on the diagnosis of pancreatic cancer (ductal adenocarcinoma of the pancreas).  MicroRNAs (or sometimes abbreviated miR) are small (18 to 25 nucleotide) non-coding RNA […]

SOX Chemo Regimen as 2nd Line for Pancreatic Cancer

Acronyms in medicine are often a hoot.  We have the four-drug combination called FOLFIRINOX for advanced pancreatic cancer (ductal adenocarcinoma of the pancreas).  Recently, here at Pancreatica we reported on a study of a three-drug version of the above termed: OFF.   Now comes a review of the regimen of S-1 plus oxaliplatin by Japanese researchers, […]

Page 17 of 37« First...10...1516171819...30...Last »